8-K 1 d8k.htm FORM 8-K Form 8-K

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 10, 2005

 


 

DrugMax, Inc.

(Exact name of registrant as specified in its charter)

 


 

STATE OF NEVADA   1-15445   34-1755390

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

312 Farmington Avenue

Farmington, CT 06032-1968

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (860) 676-1222

 


 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c)) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 8.01 Other Events.

 

On February 10, 2005, DrugMax, Inc. issued a press release regarding that status of its integration plan related to its recently completed merger. A copy of the press release, which is incorporated by reference herein and made a part hereof, is filed with this Current Report on Form 8-K as Exhibit 99.1.

 

Item 9.01 Financial Statements and Exhibits.

 

Exhibit
Number


 

Exhibit Description


99.1   Press Release dated February 10, 2005

 

2


SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.

 

DRUGMAX, INC.
By:  

/s/Edgardo Mercadante


    Edgardo Mercadante, Chief Executive Officer

 

Dated: February 10, 2005

 

3


EXHIBIT INDEX

 

Exhibit
Number


 

Exhibit Description


99.1   Press Release dated February 10, 2005

 

4